Pathophysiology and treatment of the dyslipidemia of insulin resistance

被引：18

作者：

Cohn G. ^{[1
]}

Valdes G. ^{[1
]}

Capuzzi D.M. ^{[1
]}

机构：

[1] Cleveland Clinic Florida, Weston, FL 33331

来源：

Current Cardiology Reports | 2001年 / 3卷 / 5期

关键词：

Insulin Resistance; Metformin; Gemfibrozil; Orlistat; Insulin Resistance Syndrome;

D O I：

10.1007/s11886-001-0059-0

中图分类号：

学科分类号：

摘要：

Insulin resistance, and the compensatory hyperinsulinemia that results, has been linked to a host of defects including glucose intolerance, diabetes, hypertension, dyslipidemia, endothelial dysfunction, impaired fibrinolysis, and subclinical inflammation. Patients with this metabolic syndrome have a markedly increased risk for the development of atherothrombotic cardiovascular disease. The characteristic dyslipidemia of insulin resistance consists of elevated triglyceride and triglyceride-rich lipoprotein levels, low levels of high-density lipoprotein cholesterol, and increased concentrations of small, dense low-density lipoprotein cholesterol. Management of this dyslipidemia typically involves a dual approach. Lifestyle modification is an essential component of any successful treatment plan, but alone is usually insufficient to correct these lipoprotein abnormalities. Medications that diminish insulin resistance and directly alter lipoproteins are also necessary in the majority of cases. Combinations of therapeutic agents are often required to optimize attainment of treatment goals. Copyright © 2001 by Current Science Inc..

引用

页码：416 / 423

页数：7

共 43 条

[31]

Baron A.D., Vascular reactivity, Amer J Cardiol, 84, (1999)

[32]

Petrie J.R., Ueda S., Webb D.J., Et al., Endothelial nitric oxide production and insulin sensitivity: A physiological link with implications for pathogenesis of cardiovascular disease, Circulation, 93, pp. 1331-1333, (1996)

[33]

Schmidt M.I., Duncan B.B., Sharrett A.R., Et al., Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study, Lancet, 353, pp. 1649-1652, (1999)

[34]

Haffner S.M., Alexander C.M., Cook T.J., Et al., Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study, Arch Int Med, 159, pp. 2661-2667, (1999)

[35]

Freeman D.J., Norrie J., Sattar N., Et al., Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the west of Scotland Coronary Prevention Study, Circulation, 103, pp. 357-362, (2001)

[36]

Knopp R.H., Drug treatment of lipid disorders, N Engl J Med, 341, pp. 498-511, (1999)

[37]

Manninen V., Tenkanen L., Koskinen P., Et al., Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment, Circulation, 85, pp. 37-45, (1992)

[38]

Rubins H.B., Robins S.J., Collins D., Et al., Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol, N Engl J Med, 341, pp. 410-418, (1999)

[39]

Effect of Fenofibrate on Progression of Coronary Artery Disease in Type 2 Diabetes: The Diabetes Atherosclerosis Intervention Study, Lancet, 357, pp. 905-910, (2001)

[40]

Capuzzi D.M., Morgan J.M., Brusco O.A., Intenzo C.M., Niacin dosing: Relationship to benefits and adverse effects, Curr Atheroscler Rep, 2, pp. 64-71, (2000)

← 1 2 3 4 5 →